3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
9
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Hemorrhage
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cyst
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neurotoxicity Syndromes
1
Myofibroma
1
Multiple Myeloma
1
Metabolic Diseases
1
Melanoma
1
Interventions
Cisplatin
21
Radiotherapy
16
Fluorouracil
16
Paclitaxel
15
Irinotecan
8
Docetaxel
8
Neoadjuvant Therapy
6
Drug Therapy
5
tislelizumab
4
sintilimab
4
Surgical Procedures, Operative
4
Radiation
4
Oxaliplatin
4
Leucovorin
4
Esophagectomy
4
Capecitabine
4
toripalimab
3
pembrolizumab
3
TP protocol
3
Chemotherapy, Adjuvant
3
S 1 (combination)
2
Levoleucovorin
2
Injections
2
Cetuximab
2
Carboplatin
2
lenvatinib
1
irinotecan sucrosofate
1
durvalumab
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Esophageal Squamous Cell Carcinoma
×
Saline Solution
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled